Notice of Intent to Publish a Funding Opportunity Announcement for Back Pain Consortium (BACPAC) Research Program: Phase 2 Clinical Trials (UG3/UH3) (Clinical Trial Required)

0
34
Grants.Gov Federal grants application process

Opportunity ID:310184
Opportunity Number:NOT-AR-19-025
Opportunity Title:Notice of Intent to Publish a Funding Opportunity Announcement for Back Pain Consortium (BACPAC) Research Program: Phase 2 Clinical Trials (UG3/UH3) (Clinical Trial Required)
Opportunity Category:Discretionary
Opportunity Category Explanation:
Funding Instrument Type:Cooperative Agreement
Category of Funding Activity:Health
Category Explanation:
CFDA Number(s):93.846
Eligible Applicants:State governments
County governments
City or township governments
Special district governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Small businesses
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Additional Information on Eligibility:
Agency Code:HHS-NIH11
Agency Name:Department of Health and Human Services
National Institutes of Health
Posted Date:Nov 05, 2018
Last Updated Date:Nov 05, 2018
Estimated Synopsis Post Date:Nov 21, 2018
Fiscal Year:2019
Award Ceiling:
Award Floor:
Estimated Total Program Funding:
Expected Number of Awards:4
Description:NIAMS intends to publish a Funding Opportunity Announcement (FOA) soliciting clinical trial applications focused on new and improved diagnostic and treatment modalities for chronic low back pain. The clinical trials will be supported in two phases, a milestone driven planning phase (UG3) and an implementation phase (UH3). Conduct of the study will be carried out at the Clinical Trial Network on Pain Research (CTNPR) Clinical Sites. CTNPR will also provide Data Management and Clinical Coordination support during the conduct of the trials and consultative services during the planning phase. This Notice is being provided to allow potential applicants enough time to develop meaningful collaborations and responsive projects. This FOA is expected to be published in November 2018 with an expected application due date in March 2019. This FOA will utilize the UG3/UH3 activity code. Details of the planned FOA are provided below. Public Law 115-141, the Consolidated Appropriations Act of 2018 (signed March 23, 2018) includes a requirement that grantees from for-profit applicant organizations must provide a 50% match and/or in-kind contribution of all federally awarded dollars under the grant award (direct costs, as well as facilities and administrative costs) for research related to opioid addiction, development of opioid alternatives, pain management and addiction treatment. Matching Requirement: A grantee from a for-profit organization funded under this funding opportunity announcement must match funds or provide documented in-kind contributions at a rate of not less than 50% of the total-Federally awarded amount, as stipulated by Public Law 115-141, the Consolidated Appropriations Act of 2018.The applicant will be required to demonstrate that matching funds and/or in-kind contributions are committed or available at the time of, and for the duration of, the award. Applications must identify the source and amount of funds proposed to meet the matching requirement and how the value for in-kind contributions was determined. All matching funds and/or in-kind contributions must be used for the portion of allowable project costs not paid by Federal funds under the grant award. NIH will not be the recipient, nor serve as a pass-through entity, of any such matching funds and/or in-kind contributions required under this announcement. See 45 CFR 75.306 for additional details.
Version:1





Visit the Official Webpage For More Details on Notice of Intent to Publish a Funding Opportunity Announcement for Back Pain Consortium (BACPAC) Research Program: Phase 2 Clinical Trials (UG3/UH3) (Clinical Trial Required)